Brain metastases occur in 20-40% of advanced stage cancers and represent the most prevalent adult intracranial malignancy 1 . Current clinical management of brain metastases affords limited disease control and most patients succumb to tumour progression less than 12 months after diagnosis 1,2 ; better therapeutic strategies are urgently needed. Recent work has begun to describe the cellular and molecular interactions responsible for brain metastasis. Circulating cancer cells first traverse the blood-brain barrier (BBB) 3,4 to enter the parenchyma, where they co-opt the microvasculature 5,6 . However, the vast majority of cancer cells that infiltrate the brain perish, rejected by astrocytes 6 . The astrocyte network serves a protective role in the central nervous system 7,8 . In brain metastasis, reactive astrocytes generate the protease plasmin and cytotoxic cytokines. Brain metastatic cells counter this defence with serpin inhibitors of plasminogen activator 6 . Yet, astrocyte-cancer cell interactions may not be uniformly antagonistic: brain metastases contain abundant reactive astrocytes 8 , and astrocytes can exert a beneficial effect on cancer cell co-cultures 9 .
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neuronal receptor PCDH7, encoded by PDCH7, one of a small group of genes upregulated in brain metastatic cells from both breast and lung tumours 3, 6, 12 . Protocadherins are integral membrane proteins that direct cell-cell contacts by homophilic interaction, and PCDH7 is the only protocadherin expressed predominantly in the brain 15, 16 . PCDH7 levels were higher in brain metastatic derivatives than in parental cell lines ( Fig. 1f , Extended Data Fig. 2a, b ), and higher than in matched derivatives highly metastatic to bone or lung but not brain ( Fig. 1h ; refer to Extended Data Fig. 1b ). The PCDH7 level in brain metastatic cells was higher than in astrocytes, microglia or endothelial cells ( Fig. 1g, Extended Data Fig. 2d ).
In clinical cohorts of TNBC, the expression of PCDH7 and CX43 (also known as GJA1) in primary tumours was associated with brain, but not bone or lung metastasis (Fig. 1i ). Up to 70% of relapses in patients with NSCLC include brain metastases 17 ; contributing disproportionately to survival 18 . CX43 and PCDH7 expression was associated with decreased metastasis-free survival of NSCLC patients in three cohorts (Fig. 1j, Extended Data Fig. 2e ). These results all support the relevance of PCDH7 and Cx43 in brain metastasis.
PCDH7 directs carcinoma-astrocyte gap junctions
Brain metastatic cells depleted of either PCDH7 or Cx43 using short hairpin RNAs (shRNAs) (Extended Data Fig. 2f , g) showed reduced capacity for dye transfer to astrocytes ( Fig. 2a, Extended Data Fig. 3a ), on par with the pan-connexin inhibitor, carbenoloxone (Extended Data Fig. 3b ). Cadherins may establish homophilic binding between adjacent cells 19 . We proposed that astrocyte PCDH7 might participate in the formation of gap junctions with brain metastatic cancer cells, similar to gap junctions between astrocytomas and neighbouring astrocytes 20, 21 . Indeed, PCDH7 depletion in astrocytes (Extended Data Fig. 3c ) inhibited dye transfer from MDA231-BrM2 cells (Extended Data Fig. 3d ).
Human brain microvascular endothelial cells (HBMECs) have no detectable PCDH7 expression and express low levels of Cx43 (Extended Data Fig. 2d ). Despite low gap junction communication between cancer cells and HBMECs (Extended Data Fig. 3e ), dye transfer between cancer cell and astrocyte was favoured over dye transfer between cancer cell and HBMECs (Extended Data Fig. 3f ). Primary microglia cells expressed very low levels of Cx43 and PCDH7 ( Fig. 1g ) and did not accept calcein from cancer cells (Extended Data Fig. 3g ). Thus, PCDH7 directs cancer cells to form Cx43 gap junctions with astrocytes preferentially.
To detect Cx43-PCDH7 interactions in live cells, we used a split luciferase complementation assay 22 . Constructs encoding PDCH7 and CX43 fused to the N-terminal (NLuc) and C-terminal (CLuc) halves of firefly luciferase were expressed in non-green fluorescent protein (GFP)-luciferase-labelled parental cells. When NLuc and CLuc cytoplasmic domains come into proximity, luciferase activity is reconstituted (Extended Data Fig. 4a ). Cx43 self-assembly served as positive control. We detected specific luciferase activity in cells expressing both Cx43-CLuc and PCDH7-NLuc (Extended Data Fig. 4b ), consistent with Cx43 and PCDH7 interaction within the same cell. The expression levels of PCDH7 and Cx43 luciferase chimaeras were comparable to endogenous levels (Extended Data Fig. 4c ). Astrocytes increased luciferase signal in cancer cells after co-culture (Extended Data Fig. 4d ), suggesting that astrocyte Cx43 and PCDH7 induce further clustering of cancer cell Cx43-CLuc and PCDH7-NLuc. No interaction was detected between Cx43-CLuc and N-cadherin or E-cadherin fused with NLuc (Extended Data Fig. 4e -g).
Cx43 and PCDH7 mediate brain metastasis
shRNA-mediated depletion of either Cx43 or PCDH7 in breast cancer and lung cancer cells inhibited brain metastases growth in both immunocompetent ( Fig. 2b ) and xenograft models, (Fig. 2c, d and Extended Data Fig. 5a , b); this did not affect the formation of lung lesions (Extended Data Fig. 5c ).
The Cx43(T154A) mutant assembles hemichannels but lacks channel function 23 . Cx43(T154A) re-expressed in Cx43-depleted brain metastatic cancer cells (Extended Data Fig. 5d ) was unable to mediate calcein transfer from astrocyte to MDA231-BrM cells ( Fig. 2e ). grey) . Top right, haematoxylin and eosin (H&E) staining of resected brain metastasis (T) and parenchyma (P). Bottom, immunohistochemistry of adjacent sections for GFAP (left) and Cx43 (right). Scale bars, 10 μm; n = 6 patient samples. b, Cx43 expression is increased in brain metastases (Mets) compared with primary (Pri) and normal (Norm) tissue. Representative images of Cx43 staining in clinical samples from triple-negative breast cancer (TNBC) and non-small cell lung carcinoma (NSCLC). Proportion of Cx43-positive samples was quantified in primary tumours (TNBC n = 98, NSCLC n = 138), brain metastases (TNBC n = 117; NSCLC n = 91) and normal lung tissues (n = 75). Scale bars, 100 μm. c, Top, GFP + H2030-BrM3 cells (green) are surrounded by GFAP + activated astrocytes (red) in the brain parenchyma at early (day 7) and later (day 21) time points after intracardiac inoculation in mice. Blue, collagen IV (ColIV) staining in vessels. Scale bars, 10 μm. Bottom, Cx43 staining (arrowhead) at the interface of GFP + H2030-BrM3 (green) and GFAP + astrocytes (blue f-h, Cx43 and PCDH7 western blotting in the indicated parental and brain metastatic derivatives (f, n = 3 independent experiments), in brain metastatic cells compared to brain cell types (g, n = 2 independent experiments), and in the MDA231 derivatives metastatic to brain, lung (LM) or bone (BoM) (h, n = 2 independent experiments). Full blots are shown in Supplementary Data. i, j, Kaplan-Meier plots of brain metastasis-free survival in 189 cases of TNBC (i) and 129 cases (MSKCC set2) and 58 cases (GSE3141) of lung adenocarcinoma (j), on the basis of CX43 and PCDH7 expression in the primary tumour.
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Wild-type Cx43 rescued brain metastatic activity in Cx43-depleted MDA231-BrM and H2030-BrM cells, whereas Cx43(T154A) did not ( Fig. 2f , Extended Data Fig. 5e ). These observations support a model in which PCDH7 directly interacts with Cx43 to assemble functional gap junctions between cancer cells and astrocytes ( Fig. 2f ). We defined the stage at which PCDH7 and Cx43 contribute to the formation of brain metastases using short-term metastasis assays with MDA231-BrM2 cells. In this model, extravasation across the BBB is complete 7 days after inoculation, vascular co-option and overt outgrowth occur by day 14 (ref. 6) . Cx43 or PCDH7 depletion in the cancer cells did not significantly diminish the number of GFP + cancer cells in the brain parenchyma at day 7 (Extended Data Fig. 6a ). Fourteen days after inoculation, micrometastases resulting from Cx43-or PCDH7depleted cells showed decreased proliferation (Extended Data Fig. 6b ). In ex vivo brain slice assays 6 , Cx43-or PCDH7-depleted cells displayed increased cleaved caspase 3 staining (Extended Data Fig. 6c ) and maintained vascular contacts (Extended Data Fig. 6d ). Thus, cancer cellastrocyte gap junction channels support brain metastasis growth after extravasation and vascular cooption.
Cancer cells trigger astrocyte cytokine release
To determine the mechanism behind Cx43-mediated brain metastatic growth, we assayed cancer cell gene expression by translating ribosome affinity purification (TRAP) 24 (Extended Data Fig. 7a ). We expressed the enhanced GFP (eGFP)-tagged L10a ribosomal subunit in MDA231-BrM2 cells with either basal or reduced Cx43 expression. After cancer cell-astrocyte co-culture, we immunoprecipitated eGFPtagged polysomes and sequenced the associated mRNA (Extended Data Fig. 7b , c). The gene expression patterns revealed that IFN and NF-κB pathways in brain metastatic cells were activated after astrocyte co-culture in a Cx43-dependent manner (Fig. 3a ). Conditioned media from the co-cultures was sufficient to activate the IFN and NF-κB signalling in the cancer cells, as determined by phosphorylation of STAT1 and NF-κB p65 (Fig. 3b , Extended Data Fig. 7d ). Cx43 channel function was required for this effect (Fig. 3c ). of brain metastatic lesions formed by control (Ctrl), Cx43-depleted (CX43 sh1), or PCDH7-depleted (PCDH7 sh1/2) brain metastatic cells in the MDA231 xenograft model or 393N1 syngeneic models of brain metastasis (n = 3 independent experiments, n = 8-10 mice per group). All source data from mouse experiments are in Supplementary Information. e, f, Wild type (WT) or T154A mutant (Mut) Cx43 was re-expressed in Cx43-depleted (CX43 sh2) MDA231-BrM2 cells. Cells were subjected to astrocyte dye transfer analysis by flow cytometry (e, n = 3 independent experiments), or to brain metastasis assays and BLI quantification (f, n = 2 independent experiments, 9 mice per group). g, Schematic summary of Cx43-and PCDH7-mediated interactions between cancer cells and astrocytes in brain metastasis.
Figure 3 | Gap junctions activate STAT1 and NF-κB pathways in cancer cells. a,
Signalling pathway analysis of TRAP RNA-seq data from MDA231-BrM2 cells after co-culture with astrocytes. Control or Cx43depleted MDA231-BrM2 cells expressing an eGFP-L10a ribosomal protein fusion were co-cultured with astrocytes for 24 h before polysome immunoprecipitation and mRNA sequencing. Heatmap depicts blue (downregulated) and red (upregulated) pathways. n = 2 biological replicates. b, c, STAT1 and NF-κB p65 phosphorylation (p-p65) in MDA231-BrM2 cells after a 2 h incubation with conditioned media (CM) from indicated cancer cell/astrocyte co-culture. Media samples were collected after 24 h co-culture of astrocytes with control or Cx43-depleted MDA231-BrM2 cells (b), or from Cx43-depleted MDA231-BrM2 cells that were transduced with wild-type Cx43 or Cx43(T154A) mutant (c) (n ≥ 3 independent experiments in b and c). d, Relative mRNA levels of IFNA1 and TNF in human astrocytes re-isolated after co-culture with MDA231-BrM2 cancer cells. Data are mean ± s.e.m. (from n = 3 biological replicates in 2 independent experiments). e, f, Quantification of BLI signal from brain metastases formed by control or STAT1-knockdown (STAT1 sh1/2) Kras/p53-393N1 cells (e), and SR-IκBα MDA231-BrM2 cells (f) (n = 2 independent experiments, with 12 mice total per group in e and 10 mice total per group in f). BrM:
Ctrl sh
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IFNα, TNF and TGFα accumulated in conditioned media from MDA231-BrM2 cell-astrocyte co-cultures in a gap-junction-dependent manner (Extended Data Fig. 8a, b ). MDA231-BrM2 cells, either alone or co-cultured with astrocytes, did not express these cytokines by TRAP RNA-sequencing (RNA-seq; data not shown). Upregulation of TNF and IFNA1 mRNA was detected in astrocytes re-isolated after co-culture ( Fig. 3d ). Addition of IFNα or TNF inhibited brain metastatic cancer cell apoptosis in response to chemotherapy (Extended Data Fig. 8c ). In two syngeneic mouse models, knockdown of STAT1 in brain metastatic cells (Extended Data Fig. 8d ) reduced brain metastasis ( Fig. 3e , Extended Data Fig. 8e ). Inhibition of NF-κB by overexpression of IκBα super suppressor (SR-IκBα) 25 in brain metastatic cells (Extended Data Fig. 8f ) also suppressed brain metastasis (Fig. 3f) . These results suggest that heterocellular gap junction communication elicits production of IFNα and TNF in astrocytes, triggering STAT1 and NF-κB survival signals in cancer cells.
Cancer cells transfer cGAMP to astrocytes
Upregulation of both IFNα and TNF was reminiscent of a cellular response to dsDNA 26 . Cytosolic dsDNA activates the cGAS-STING pathway, an innate immune response against viral infection 27 , in which cyclic GMP-AMP synthase (cGAS) senses cytosolic dsDNA and synthesizes the second messenger 2′3′-cyclic GMP-AMP (cGAMP). cGAMP binding to STING triggers phosphorylation and activation of TBK1 and IRF3, nuclear accumulation of IRF3, and transcriptional activation of IRF3 target genes IFNA1 and TNF 10 .
Co-incubation of MDA231-BrM2 cells and astrocytes triggered Cx43-dependent phosphorylation of TBK1 and IRF3 (Fig. 4a , Extended Data Fig. 9a ). Nuclear accumulation of IRF3 occurred only in co-cultured astrocytes, and not in either cell type alone (Fig. 4b ). STING knockdown in mouse astrocytes (Extended Data Fig. 9b ) inhibited their ability to respond to mouse LLC-BrM cells with IRF3 phosphorylation (Fig. 4c ), or IFNα and TNF production (Extended Data Fig. 9c ), indicating the need for STING activity in astrocytes. We inoculated LLC-BrM cells into syngeneic STING-mutant or wild-type C57Bl6 mice and found that host STING inactivation suppressed brain metastasis by these cells (Fig. 4d , Extended Data Fig. 9d ).
We next investigated the source of astrocyte STING activation. Subcellular fractionation (Extended Data Fig. 9e , f) and immunofluorescence (Extended Data Fig. 9g ) showed cytosolic dsDNA in human cancer cell lines and not in astrocytes and other non-neoplastic cells. We detected cGAMP by liquid chromatography tandem mass spectrometry (LC-MS/MS) in MDA231-BrM2 cells, but not in astrocytes ( Fig. 4e , Extended Data Fig. 9h ). Co-culture of MDA231-BrM2 cells with astrocytes further increased cGAMP levels in a Cx43-dependent manner (Fig. 4f ). Given the presence of both cytosolic dsDNA and cGAMP in cancer cells (Extended Data Fig. 9i , j), we next identified which molecule was responsible for astrocyte STING pathway activation. cGAS knockdown cancer cells (Extended Data Fig. 9k ) induced little IRF3 phosphorylation ( Fig. 4g ), TNF or IFNα production (Extended Data Fig. 9l ) in co-cultured astrocytes. Moreover, cGAS-depletion in cancer cells led to reduced brain metastasis (Extended Data Fig. 9m ).
Together, these results support a model in which brain metastatic cancer cells contain cytosolic dsDNA and cGAMP and engage astrocytes in Cx43-based gap junctions. The gap junctions allow passage of cGAMP from cancer cells into astrocytes to trigger TBK1 and IRF3 activation and production of IFNα and TNF. These cytokines activate STAT1 and NF-κB signalling in cancer cells to support cancer cell growth and survival under microenvironmental and chemotherapeutic stresses (Fig. 4h ).
Gap junction directed therapy
Genetic evidence that inhibition of gap junction signalling decreases brain metastasis prompted testing pharmacological suppressors of gap junction activity. In addition to anti-inflammatory activity, meclofenamate inhibits Cx43 gap junction gating 28 and inhibits epileptogenesis in animal models 29 . Tonabersat is a benzopyran derivative that binds to a unique stereoselective binding site in astrocytes 30, 31 and inhibits gap-junction-mediated processes including cortical spreading depression 32 and trigeminal ganglion neuronal-satellite cell signalling 33 . Both tonabersat and meclofenamate inhibited dye transfer from astrocytes to cancer cells ( Fig. 5a ) and release of IFNα and TNF in astrocyte cancer cell co-cultures (Fig. 5b) . Treatment with either compound inhibited brain metastases in xenograft and immunocompetent models (Fig. 5c, Extended Data Fig. 10a, b ), but did not restrict lung metastasis (Extended Data Fig. 10c, d) . Neither drug altered the astrocyte response to cGAMP (Extended Data Fig. 10e ). 
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To test the effect of Cx43 or PCDH7 depletion in established metastases, we transduced MDA231-BrM2 cells with doxycycline-inducible shRNA expression vectors (Extended Data Fig. 10g ). Red fluorescence protein (RFP) under the control of the same promoter provided a marker of hairpin expression (Extended Data Fig. 10f ). Doxycycline treatment began 14 days after inoculation 3,6 (Extended Data Fig. 10h, Fig. 5d ), and reduced brain metastatic burden 3 weeks later (Fig. 5e, f) .
Brain metastases show pronounced resistance to chemotherapy 34 . Carboplatin crosses the BBB 35 , modestly improving overall survival in patients with brain metastases from breast 36 or lung cancer 37 . Carboplatin alone (50 mg kg −1 every fifth day) starting on day 14 inhibited brain metastasis to a similar extent to Cx43 or PCDH7 depletion (Fig. 5e, f) ; the combination of carboplatin and Cx43-or PCDH7depletion further reduced the metastatic burden ( Fig. 5e, f) . Treatment with either tonabersat (10 mg kg −1 ) or meclofenamate (20 mg kg −1 ) as single agents (Fig. 5g ) significantly inhibited progression of metastatic lesions. Addition of carboplatin to either agent profoundly inhibited brain metastasis (Fig. 5g ).
Discussion
The brain represents a formidable metastatic target, of which astrocytes are a predominant feature. We find that cancer cells use PCDH7 to engage astrocytes selectively in vital Cx43 gap junctions. Cadherins mediate cell-cell communication in development and tissue homeostasis 19 , particularly in the nervous system 38 . Remarkably, brain metastatic cells adopt a cadherin whose normal expression is largely confined to the brain 15 . PCDH7 joins the sialyltransferase ST6GALNAC5 (ref.
3) and neuroserpin 6 as brain-restricted components that metastatic cells from breast and lung carcinomas selectively express to colonize the brain. Functional Cx43-based gap junctions between cancer cells and astrocytes allow cancer cells to disseminate cGAMP to astrocytes. This activates the astrocytic cGAS-STING pathway and release of cytokines including IFNα and TNF, which provide a growth advantage for brain metastatic cells by protecting against physiological and chemotherapeutic stresses.
cGAMP transfer from cancer cell to astrocyte is reminiscent of cGAMP spread to adjacent cells in the anti-viral context 39, 40 . However, unlike homotypic transfer of cGAMP to bystander cells to intensify the immune response, brain metastatic cells shunt cGAMP into neighbouring host astrocytes to trigger downstream signalling that supports metastatic outgrowth. This pro-metastatic process contrasts with previous reports of tumour STING activation and subsequent host immune cell extracranial anti-tumour response 41, 42 and highlights the profound impact of stromal context.
Brain metastases are a major contributor to cancer mortality, with few therapeutic options available. Cancer cell dependency on Cx43-PCDH7 gap junctions for survival, and outgrowth of metastatic lesions suggests a therapeutic opportunity. Our pre-clinical results using combinations of chemotherapy and gap junction modulators provide a proof-of-principle for the therapeutic potential of these interventions against brain metastasis. . c, Tonabersat or meclofenamate was administered daily starting one day after cancer cell inoculation in mice. Brain metastatic lesions were quantified based on BLI (n = 2 independent experiments; 8 mice total per group). d, GFP staining of 14-day brain metastatic lesions. Representative images show large, progressive lesions. DAPI, nuclear staining. Scale bars, 40 μm; n = 10 mice. e-g, Fourteen days after inoculation with MDA231-BrM2 cells transduced with inducible control, CX43 or PCDH7 shRNAs, mice were treated with doxycycline and carboplatin. e, Representative images of matched ex vivo brain BLI and red fluorescence imaging. f, Brain metastatic lesions were quantified based on BLI (2 independent experiments with n = 10 total mice per group). g, Fourteen days after inoculation with MDA231-BrM2 cells, mice were treated with tonabersat, meclofenamate, and carboplatin. Following the indicated regimens, brain metastatic lesions were quantified based on BLI (2 independent experiments with n = 9 mice total per group). 
Article reSeArcH
MethOdS Cell culture. Human MDA-MB-231, mouse MMTV-neu, and mouse Lewis lung cancinoma (LLC) and their metastatic derivatives, MDA-MB-231-BrM2 (MDA231-BrM), ErbB-BrM, and LLC-BrM respectively, and the mouse 373N1, 393N1, 482N1 and 2691N1 cell lines were cultured in DMEM with 10% FBS and 2 mM l-glutamine. Human H2030 cells and metastatic derivatives H2030-BrM3 (H2030-BrM) were cultured in RPMI 1640 medium supplemented with 10% FBS and 2 mM l-glutamine. For lentivirus production, 293T cells were cultured in DMEM supplemented with 10% FBS and 2 mM l-glutamine. Human primary astrocytes, mouse primary astrocytes, HBMECs, adult dermal fibroblasts, and microglia were cultured in media specified by the supplier (ScienCell), and used between passages 2 and 6. All cells tested negative for mycoplasma. Animal studies. All experiments using animals were performed in accordance with protocols approved by the MSKCC Institutional Animal Care and Use Committee. Athymic NCR nu/nu mice (NCI-Frederick), Cr:NIH bg-nu-xid mice (NCI-Frederick), B6129SF1/J, C57BL/6J-Tmem173gt/J 43 'golden ticket' , and C57/ Bl/6J mice (Jackson Laboratory) were used at 5-6 weeks of age. For long-term brain metastasis assays we followed previously described procedures 3 . In brief, 1 × 10 4 MDA231-BrM2 cells, 5 × 10 4 H2030-BrM3 cells, 5 × 10 4 LLC-BrM or 1 × 10 5 393N1 cells suspended in 100 μl PBS were injected into the left cardiac ventricle. At the experimental endpoint, anaesthetized mice (ketamine 100 mg kg −1 , xylazine 10 mg kg −1 ) were injected retro-orbitally with d-luciferin (150 mg kg −1 ), before euthanasia, dissection of brain and quantified by ex vivo BLI. For short-term (7-day and 14-day) brain metastasis experiments, we introduced 5 × 10 5 cells. Where relevant, TRITC dextran (70 kDa) (Life Technologies) was intravenously injected to stain vascular structures before dissection. For lung colonization assays, 2 × 10 5 MDA231-BrM2 cells in 100 μl PBS were injected into the lateral tail vein. For orthotopic tumour implantation, 5 × 10 3 cells in 50 μl of 1:1 mix of PBS/growthfactor-reduced Matrigel (BD Biosciences) were injected into the fourth right mammary fat pad of female mice. For inducible knockdown experiments, mice were given doxycycline hyclate (Sigma-Aldrich) in the drinking water (2 mg ml −1 ) and the diet (Harlan) 14 days after injection of cancer cells. For drug treatment experiments, mice were intraperitoneally injected with carboplatin (Hospira) (5 mg kg −1 per 5 days), tonabersat (MedChem Express) (10 mg kg −1 day −1 ), or meclofenamic acid sodium salt (Sigma-Aldrich) (20 mg kg −1 day −1 ). Vehicle (10% DMSO in polyethylene glycol 400) was used in control mice. Quantification of tumour burden was by BLI, performed using an IVIS Spectrum Xenogen instrument (Caliper Life Sciences) and analysed using Living Image software v.2.50. See Source Data. A priori sample size determination for animal experiments was determined by Mead's Resource Equation: 10 animals per treatment group in an experimental design of three groups, without further stratification, gives 28 degrees of freedom, an adequate sample size. Eight animals per treatment group gives 24 degrees of freedom, also acceptable. Therefore, for brain metastasis assays, 8-10 mice were used in each group; exact numbers for each experimental series are included in the relevant figure legends. For drug treatment experiments, mice were inoculated with cancer cells and randomly assigned to treatment groups. Mice dying less than 24 h after tumour inoculation were excluded from analysis. Gap junction modulators and chemotherapeutic agents were blindly administered in the MSKCC Antitumour Assessment Core. Immunohistochemical staining. Mouse brains were fixed with 4% paraformaldehyde, sectioned by vibratome (Leica) or cryostat (Leica) and stained following established protocols 6 . For brain slice assays 6 , 250-μm thick slices of adult mouse brain were prepared with a vibratome (Leica) and placed on top of 0.8 μm pore membranes (Millipore) in brain slice culture medium (DMEM, complete HBSS, 5% FBS, 1 mM l-glutamine, 100 IU ml −1 penicillin, 100 μg ml −1 streptomycin). Approximately 3 × 10 5 cancer cells were placed on the surface of the slice. After 48 h of incubation, brain slices were fixed with 4% paraformaldehyde, and stained. For immunostaining in chamber slide cultures, cells were fixed with 4% paraformaldehyde and stained. Antibodies used for immunochemical staining are listed in Supplementary Information. Images were acquired with Zeiss Axio Imager Z1 microscope or Leica SP5 upright confocal microscope, and analysed with ImageJ, Imaris and Metamorph softwares. Antibodies used for immunostaining are listed in Supplementary Information. Knockdown and overexpression constructs. For stable knockdown of Cx43, PCDH7, cGAS and STING, we used shRNAs in GiPZ lentiviral vector. For inducible knockdown, shRNAs in TRIPZ lentivial vector were used. 1 μg ml −1 doxycycline hyclate (Sigma-Aldrich) was added to induce the expression of shRNA. Targeted sequences of shRNAs are listed in the Supplementary Information. pBabe-Puro-IK-Balpha-mut (Addgene) was used for stable expression of SR-IκBα. For expression of wild-type Cx43 (Origene) or Cx43(T154A) mutant (ACC to GCC), we used the pLVX vector. mRNA and protein detection. Total RNA was extracted using the PrepEase RNA spin kit (USB). To prepare cDNA, 1 μg of total RNA was treated using the Transcriptor First Strand cDNA synthesis kit (Roche). CX43, CX30 and CX26 expression were quantified by Taqman gene expression assay primers: (CX43: Hs00748445_s1, Mm00439105_m1; CX30: Hs00922742_s1, Mm00433661_ s1; CX26: Hs00269615_s1, Mm00433643_s1; Applied Biosystems). Relative gene expression was normalized to expression of B2M (β2-microglobulin; Hs99999907_m1, Mm00437762_m1). The PCDH7 primer pair was designed to detect all PCDH7 isoforms: 5′-AGTTCAACGTGGTCATCGTG-3′ (sense), 5′-ACAATCAGGGAGTTGTTGCTC-3′ (antisense). Reactions were performed using SYBR Green I Master Mix (Applied Biosystems). Quantitative expression data were analysed using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). For western immunoblotting, cell pellets were lysed with RIPA buffer and protein concentrations determined by BCA Protein Assay Kit (Pierce). Protein lysates of primary human astrocytes, microglia and HBMECs were purchased from ScienCell. Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes (BioRad). Antibodies used for western blotting are listed in Supplementary Table 1 . Dye transfer and EdU transfer assays. Monolayers of cancer cells or astrocytes were labelled with 2.5 μg ml −1 calcein Red-Orange AM dye (Life Technologies) at 37 °C for 30 min. Single-cell suspensions were mixed at a ratio of 2:1 labelled: unlabelled cells for 6 h. Certain experiments used a mix of three cell populations, MDA231-BrM2 (GFP + ), HBMECs (pre-labelled with Cell Proliferating Dye Fluor@670, eBioscience), and unlabelled astrocytes. Dye transfer was visualized by Zeiss LSM 5 Live confocal microscopy (20-min time-lapse) or quantified by FACSCalibur flow cytometry (BD Biosciences). Cancer cell and astrocyte co-culture experiments. Astrocytes and cancer cells were mixed at ratio of 1:1. For apoptosis assays, overnight co-cultures were treated with 500 ng ml −1 sFasL (Peprotech) in serum-free media, 500 nM carboplatin (Sigma-Aldrich) or 25 nM paclitaxel (Sigma-Aldrich) for 24 h. Single-cell suspensions were stained with allophycocyanin-conjugated cleaved caspase 3 antibody (Cell Signaling), apoptotic GFP + cancer cells were detected by flow cytometery. For conditioned media analysis, media were collected after 24 h, and cytokines in the conditioned media were either identified using Human Cytokine Array (R&D systems) or measured by human or mouse IFNα or TNF ELISA kits (R&D systems) as relevant. To detect the activity of IFNα or TNF in the collected conditioned media, cancer cells were treated with the collected conditioned media for 2 h and phosphorylation status of STAT1 or NF-κB p65 was determined by western blotting. For cGAMP and TANK-binding kinase 1 (TBK1)-IRF3 activation experiments, cancer cells and astrocytes were co-cultured for 18 h. To stimulate astrocytes without co-culture, astrocytes were transfected with cGAMP (4 μg ml −1 ) with Lipofectamine 2000, according to the manufacturer's protocol, as previously described 43 . The phosphorylation status of TBK1, IRF3 was determined by western immunoblotting. Nuclear translocation of IRF3 was determined by immunofluorescence staining with Zeiss LSM 5 Live confocal microscopy. cGAMP levels were determined by LC-MS/MS. Detailed methods for cGAMP detection and quantification are described in Supplementary Information. TRAP. eGFP-L10a-expressing cancer cells were co-cultured with astrocytes for 24 h. Following previously published protocols 24, 44 , mRNA purified from cancer cells was used for library construction with TruSeq RNA Sample Prep Kit v2 (Illumina) following the manufacturer's instructions. Samples were barcoded and run on a Hiseq 2000 platform in a 50 bp/50 bp paired-end run, using the TruSeq SBS Kit v3 (Illumina). An average of 50 million paired reads were generated per sample. Cytokine treatment and pathway reporter assays. Cancer cells were treated with 10 U ml −1 (39 U ng −1 ) recombinant IFNα (R&D Systems) or 10 pg ml −1 recombinant TNF (R&D Systems) in combination with carboplatin or taxol (Sigma-Aldrich) for 24 h. Apoptosis was quantified by Caspase-Glo 3/7 assay (Promega). For NF-κB reporter assays, the NF-κB responsive sequence from the pHAGE NFKB-TA-LUC-UBC-dTomato-W construct (Addgene) 45 was cloned into a pGL4.82 Renilla luciferase reporter (Promega). Cancer cells were co-transfected with this vector and a LeGO-C2 mCherry vector (Addgene). Renilla luciferase activity was determined using RenillaGlo Luciferase system (Promega). Red fluorescence signal was used to normalize transfection efficiency. Split luciferase assay. Fusion cDNAs were generated by deleting the stop codon in human CX43 (Origene), PCDH7 (Origene), CDH1 (E-cadherin; Addgene) or CDH2 (N-cadherin; Addgene) cDNAs and splicing the N-terminal or C-terminal fragment of firefly luciferase 22 (Addgene). Constructs were cloned into pLVX lentiviral expression vector and transduced into non-GFP-luciferase-labelled parental MDA-MB-231 or H2030 cells. To detect luciferase activity, 7.5 mg ml −1 d-luciferin potassium salt was added in the culture media. BLI was performed by IVIS Spectrum Xenogen instrument, using Living Image software v.2.50. Cytosolic dsDNA detection. For visualization of dsDNA, cells were immunostained with anti-dsDNA antibody. Anti-GFP antibody staining was used to delineate cancer cell bodies, DAPI to distinguish nuclei, and anti-CoxIV antibody Article reSeArcH to distinguish mitochondria. Phalloidin staining (Molecular Probe) was used to delineate astrocyte cell bodies. For quantification of dsDNA, nuclear, cytosolic and mitochondrial fractions were prepared using a mitochondria isolation kit (Thermo Scientific). DNA from all subcellular fractions was purified by QIAamp DNA mini kit (Qiagen) and quantified by QuantoFluor dsDNA system (Promega). Bioinformatic and statistical analysis. Bioinformatic analysis was performed in R (ver. 3.1.2) unless otherwise noted. The data were analysed using the TopHat2-HTSeq-DESeq2 pipeline [46] [47] [48] . Differential gene expression was compared with cooksCutoff and independentFiltering turned off. Scatter plot showing fold changes was produced using the ggplot2 package. Principal component analysis was performed using prcomp. Pathway gene response signatures were analysed and scored by the sum of z-score method 44 , as previously described 12, 49 . Multiple hypothesis testing was adjusted using the Benjamini and Hochberg false discovery rate method. Statistical analysis was performed using GraphPad software (Prism) and Student's t-test (two-tailed). P < 0.05 was considered statistically significant. Values are mean ± s.e.m. Clinical sample analysis. All tissues were obtained from the MSKCC Department of Pathology in compliance with the MSKCC Institutional Review Board under Biospecimen Research Protocol 15-204. Informed consent was obtained from all subjects. CX43 and PCDH7 transcript levels were analysed in the microarray data of primary breast cancer (EMC-MSK) and adenocarcinoma data sets (MSKCC set2, GSE3141 and GSE8893). Multiple probes mapping to the same gene were combined by selecting the probe with maximal variance across samples. TNBC subtypes were identified based either on clinical annotation of the data set or on ESR1 and ERBB2 transcript levels. The hazard ratio of the CX43 and PCDH7 values was computed based on Cox proportional hazards model, as implemented by the 'coxph' command in R. P values were calculated from a Cox proportional hazard model, with CX43 and PCDH7 expression treated as a continuous variable.
For Cx43 immunohistochemistry, normal lung tissue array (75 cases), primary TNBC tissue array (98 cases) and primary NSCLC tissue array (138 cases) were purchased from US Biomax. Paraffin-embedded tissue microarrays from brain metastases (117 case of TNBC, 91 cases of NSCLC) were obtained from the MSKCC Department of Pathology. Immunohistochemical staining for Cx43 was performed by the MSKCC Pathology Core Facility using standardized, automated protocols. For matched primary-brain metastatic lesions, Cx43 staining was quantified by positive staining area (Metamorph software). 

